E-LIB Suche - Ergebnisse für: Abrisqueta, Pau

1

First Data From Subcutaneous Epcoritamab + Polatuzumab Vedo..:

Kerr, Daniel Alan ; Lavie, David ; Avigdor, Abraham...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S217 , 2024

Link: https://doi.org/10.1016/..

2

Polatuzumab vedotin plus rituximab and lenalidomide in pati..:

Abrisqueta, Pau ; González-Barca, Eva ; Panizo, Carlos...
The Lancet Haematology. 11 (2024) 2 - p. e136-e146 , 2024

Link: https://doi.org/10.1016/..

3

Ibrutinib followed by ofatumumab consolidation in previousl..:

Abrisqueta, Pau ; González-Barca, Eva ; Ferrà, Christelle...
eClinicalMedicine. 73 (2024) - p. 102642 , 2024

Link: https://doi.org/10.1016/..

4

Epcoritamab With Rituximab + Lenalidomide (R2) in Previousl..:

Falchi, Lorenzo ; Vermaat, Joost S.P. ; Musuraca, Gerardo...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S222 , 2024

Link: https://doi.org/10.1016/..

5

Safety and efficacy of parsaclisib in combination with ritu..:

Sancho, Juan-Manuel ; Abrisqueta, Pau ; Kumar, Abhijeet...
Leukemia & Lymphoma. 65 (2024) 7 - p. 911-921 , 2024

Link: https://doi.org/10.1080/..

6

CLL-573 Characterization and Outcomes of the Spanish Patien..:

Abrisqueta, Pau ; López-Jiménez, Javier ; Osorio, Santiago...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S359 , 2024

Link: https://doi.org/10.1016/..

7

New Insights into First-Line Therapy in Diffuse Large B-Cel..:

Abrisqueta, Pau
Journal of Clinical Medicine. 13 (2024) 7 - p. 1929 , 2024

Link: https://doi.org/10.3390/..

8

Characterization and Outcomes of the Spanish Patients Inclu..:

Abrisqueta, Pau ; López-Jiménez, Javier ; Osorio, Santiago...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S184 , 2024

Link: https://doi.org/10.1016/..

9

Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in T..:

Abrisqueta, Pau ; Falchi, Lorenzo ; Nijland, Marcel...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S214 , 2024

Link: https://doi.org/10.1016/..

10

ABCL-417 First Data From Subcutaneous Epcoritamab + Polatuz..:

Alan Kerr, Daniel ; Lavie, David ; Avigdor, Abraham...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S478-S479 , 2024

Link: https://doi.org/10.1016/..

11

New therapies for relapsed or refractory aggressive B‐cell ..:

Bastos‐Oreiro, Mariana ; Abrisqueta, Pau ; Gutierrez, Antonio...
HemaSphere. 8 (2024) 4 - p. , 2024

Link: https://doi.org/10.1002/..

12

Rituximab maintenance after bendamustine-based treatment fo..:

Serna, Ángel ; Navarro, Víctor ; Iacoboni, Gloria...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

13

IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in ..:

Falchi, Lorenzo ; Vermaat, Joost S.P. ; Musuraca, Gerardo...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S496-S497 , 2024

Link: https://doi.org/10.1016/..

14

ABCL-272 Epcoritamab + R-DHAX/C Induces Deep, Durable Respo..:

Abrisqueta, Pau ; Falchi, Lorenzo ; Nijland, Marcel...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S468 , 2024

Link: https://doi.org/10.1016/..

15

From genetics to therapy: Unraveling the complexities of Ri..:

Abrisqueta, Pau ; Nadeu, Ferran ; Bosch-Schips, Jan...
Cancer Treatment Reviews. 120 (2023) - p. 102619 , 2023

Link: https://doi.org/10.1016/..